Cancer Stem Cells Market , By Cancer Form (Breast, Blood, Lung, Brain, Colorectal, Pancreatic, Bladder, Liver), By Application (Targeted CSCs, Stem Cell Based Cancer Therapy): Global Opportunity Analysis and Industry Forecast, 2019–2026
- RES4072076
- 180 Pages
- January 2020
- Healthcare
Cancer stem cells (CSCs) refer to the cells obtained from tumor that possess potential ability to perpetuate themselves through self-renewal and to generate mature cells of a particular tissue through differentiation. These cancer stem cells have versatile properties like potential to proliferate extensively, capability to develop into multiple lineage. Such cells are found in frequent tissues including brain, prostates, lung and others. This CSCs plays crucial role in therapies of cancer.
Rising tension of cancerous diseases around the world is one of the significant factor which drives global market. According to the World Health Organization (WHO), one out of six deaths are occurs due to cancers like breast cancer, lungs cancer and others. The reasons for rising count of cancerous patients are, alcohol consumption, low fruit and vegetable intake, urban air pollution, sexually transmitted HPV-infection. In addition, inaccessible diagnosis and treatment as well as late-stage presentation are common factor which causes cancer. On the other hand, stem cell research has potential to produce different type of medicines for diseases along with finding drugs that work better for individual patient.
Many recent advancements in stem cells expected to surge the market of cancer stem cells such as discovery of new bio marker- Plectin. Plectin is a structural protein in cancer stem cell that govern cancer survival and spread. Also, it can be broadly applicable for new drug development. In addition, researchers at Tel Aviv University are looking to decrease the rate of relapse in blood cancer by targeting leukemic stem cells which are often considered as most malignant. Thus, they introduced newly advanced biosensor which can target leukemic stem cells. Also, researchers are discovering genes that are active in leukemic stem cells for searching other druggable targets.
Contrary to this, issues such as stringent international regulations and involvement of ethical issues to perform human trials are declining the growth of the global market. For instance, the U.S. Department of Health and Human Services did not renew a fetal tissue research contract with the University of California San Francisco involving human fetal tissue from elective abortions to develop testing protocols. Additionally, they also announced measures to limit future research involving such tissue.
Stem cell research is the rapidly growing medical practice in Turkey. Therefore, this country is now recognized as ‘rising star of Europe in stem cell’. Turkish hospitality and friendliness is well deserved along with ‘high quality, low cost stem cell treatment’, modern laboratory equipment creating enormous opportunities for the investors of stem cells.
The breast cancer market was of $133.7 million in the 2018 year, and it is predicted to generate revenue around $295.0 by the end of 2026.Intake of alcohol and hormones, genetic influences & differences in lifestyle are the frequent cause for increasing numbers of cancer cases globally. Breast cancer is mainly considered as prevalent human malignancy along with most common reason of cancer deaths in the world. Therefore, this patients could have extensive range of pathological, clinical and molecular characteristics.
The size of stem Cell based Cancer Therapy was upto $440.3 million in the year 2018, and it is expected to generate revenue upto $896.9 million by 2026. Based on application, market is fragmented into targeted cancerous stem cell therapy and stem cell based cancer therapy. Cell based therapy is segmented into autologous SC therapy and allogenic SC therapy. It is predicted that allogenic HCT (Haematopoetic Cell Transplantation) drive the market due to various potential advantages for breast cancer (BC) such as immune mediated graft-vs-tumor and cancer free graft. In which the donor stem cells create their own immune cells, which can help to kill any cancer cells that remain after high-dose treatment. In addition, this cancer is considered as the most frequently occurring cancer in women all over the globe along with metastatic BC (breast cancer) has a high mortality rate and is it almost incurable despite chemotherapy and hormonal therapy.
The North America market generated revenue of $365.6 million in 2018, and is further anticipated to generate revenue upto $783.8 million by the end of year 2026. North America’s market is mainly led by US. As per publication of World Health Organization (WHO), one person dies from blood cancer in every nine minutes into the U.S. Thus, United States is taking more initiatives on research of cancer stem cells, along with this they are also focusing on factors such as newly developed biosensors, supportive economy, availability of expertise in healthcare domain, and large research infrastructure. Therefore it is expected to upsurge the cancer stem cells market in U.S.
Asia-Pacific market is expected to generate revenue of $367.7 Million till 2026. Asia-Pacific market is developing market for cancer stem cells as stem cell research has become a focal point for government’s plan for developing the biomedical sector. India, Japan and China are investing heavily for highly equipped laboratories with the latest advanced technology.
Some of the major players in the global cancer stem cells market are AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A. these players are initiating various steps in order strengthen their presence such as merger & acquisitions, new product development etc. For instance, in February 2019, Fluxion Biosciences launched custom liquid biopsy NGS (Next Generation Sequencing) panel development. In liquid biopsy, NGS has been applied to sequencing of circulating tumor DNA. This technology has led to noteworthy reduction in the cost of sequencing coupled with improved accuracy.
Aspect Particulars
Historical Market Estimations 2016-2018
Base Year for Market Estimation 2018
Forecast timeline for Market Projection 2019-2026
Geographical Scope North America, Europe, Asia-Pacific, LAMEA
Segmentation by Cancer Form • Breast
• Lungs
• Liver
• Pancreas
• Brain
• Bladder
• Colon
• Blood
Segmentation by application • Targeted Cancerous Stem Cells (CSCs)
• Stem Cell-based Cancer Therapy
• Others
Key Countries covered U.S., Canada, Germany, France, Spain, Russia, Japan, China, India, South Korea, Australia, Brazil, and Saudi Arabia
Key Companies Profiled • AdnaGen GmbH
• Advanced Cell Diagnostics, Inc.
• AVIVA Biosciences Corporation
• Celula, Inc.
• Epic Sciences Inc.
• Fluxion Biosciences, Inc.
• Rarecells USA Inc.
• Silicon Biosystems, S.p.A.
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.4.1. Assumptions
1.4.2. Forecast parameters
1.5. Data sources
1.5.1. Primary
1.5.2. Secondary
2. Executive Summary
2.1. 360° summary
2.2. Cancer Form
2.3. Application
3. Market Overview
3.1. Market segmentation & definitions
3.2. Key takeaways
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of consumers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of new entrants
3.3.4. Threat of substitutes
3.3.5. Competitive rivalry in the market
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. Technology landscape
3.6. Regulatory landscape
3.7. Patent landscape
3.8. Market value chain analysis
3.8.1. Stress point analysis
3.9. Strategic overview
4. Cancer Stem Cells, by Form
4.1. Breast
4.1.1. Market size and forecast, by region, 2016-2026
4.1.2. Comparative market share analysis, 2018 & 2026
4.2. Blood
4.2.1. Market size and forecast, by region, 2016-2026
4.2.2. Comparative market share analysis, 2018 & 2026
4.3. Lung
4.3.1. Market size and forecast, by region, 2016-2026
4.3.2. Comparative market share analysis, 2018 & 2026
4.4. Brain
4.4.1. Market size and forecast, by region, 2016-2026
4.4.2. Comparative market share analysis, 2018 & 2026
4.5. Colorectal
4.5.1. Market size and forecast, by region, 2016-2026
4.5.2. Comparative market share analysis, 2018 & 2026
4.6. Pancreas
4.6.1. Market size and forecast, by region, 2016-2026
4.6.2. Comparative market share analysis, 2018 & 2026
4.7. Bladder
4.7.1. Market size and forecast, by region, 2016-2026
4.7.2. Comparative market share analysis, 2018 & 2026
4.8. Liver
4.8.1. Market size and forecast, by region, 2016-2026
4.8.2. Comparative market share analysis, 2018 & 2026
4.9. Others
4.9.1. Market size and forecast, by region, 2016-2026
4.9.2. Comparative market share analysis, 2018 & 2026
5. Cancer Stem Cells Market, by Application
5.1. Targeted Cancerous Stem Cells
5.1.1. Market size and forecast, by region, 2016-2026
5.1.2. Comparative market share analysis, 2018 & 2026
5.2. Stem Cell Based cancer therapy
5.2.1. Market size and forecast, by region, 2016-2026
5.2.2. Comparative market share analysis, 2018 & 2026
5.3. Others
5.3.1. Market size and forecast, by region, 2016-2026
5.3.2. Comparative market share analysis, 2018 & 2026
6. Cancer Stem Cells Market, by Region
6.1. North America
6.1.1. Market size and forecast, by cancer form, 2016-2026
6.1.2. Market size and forecast, by application, 2016-2026
6.1.3. Market size and forecast, by country, 2016-2026
6.1.4. Comparative market share analysis, 2018 & 2026
6.1.5. U.S.
6.1.5.1. Market size and forecast, by cancer form, 2016-2026
6.1.5.2. Market size and forecast, by application, 2016-2026
6.1.5.3. Comparative market share analysis, 2018 & 2026
6.1.6. Canada
6.1.6.1. Market size and forecast, by cancer form, 2016-2026
6.1.6.2. Market size and forecast, by application, 2016-2026
6.1.6.3. Comparative market share analysis, 2018 & 2026
6.1.7. Mexico
6.1.7.1. Market size and forecast, by cancer form, 2016-2026
6.1.7.2. Market size and forecast, by application, 2016-2026
6.1.7.3. Comparative market share analysis, 2018 & 2026
6.2. Europe
6.2.1. Market size and forecast, by cancer form, 2016-2026
6.2.2. Market size and forecast, by application, 2016-2026
6.2.3. Market size and forecast, by country, 2016-2026
6.2.4. Comparative market share analysis, 2018 & 2026
6.2.5. Germany
6.2.5.1. Market size and forecast, by cancer form, 2016-2026
6.2.5.2. Market size and forecast, by application, 2016-2026
6.2.5.3. Comparative market share analysis, 2018 & 2026
6.2.6. Spain
6.2.6.1. Market size and forecast, by cancer form, 2016-2026
6.2.6.2. Market size and forecast, by application, 2016-2026
6.2.6.3. Comparative market share analysis, 2018 & 2026
6.2.7. France
6.2.7.1. Market size and forecast, by cancer form, 2016-2026
6.2.7.2. Market size and forecast, by application, 2016-2026
6.2.7.3. Comparative market share analysis, 2018 & 2026
6.2.8. Italy
6.2.8.1. Market size and forecast, by cancer form, 2016-2026
6.2.8.2. Market size and forecast, by application, 2016-2026
6.2.8.3. Comparative market share analysis, 2018 & 2026
6.2.9. Rest of the Europe
6.2.9.1. Market size and forecast, by cancer form, 2016-2026
6.2.9.2. Market size and forecast, by application, 2016-2026
6.2.9.3. Comparative market share analysis, 2018 & 2026
6.3. Asia-Pacific
6.3.1. Market size and forecast, by cancer form, 2016-2026
6.3.2. Market size and forecast, by application, 2016-2026
6.3.3. Market size and forecast, by country, 2016-2026
6.3.4. Comparative market share analysis, 2018 & 2026
6.3.5. China
6.3.5.1. Market size and forecast, by cancer form, 2016-2026
6.3.5.2. Market size and forecast, by application, 2016-2026
6.3.5.3. Comparative market share analysis, 2018 & 2026
6.3.6. Japan
6.3.6.1. Market size and forecast, by cancer form, 2016-2026
6.3.6.2. Market size and forecast, by application, 2016-2026
6.3.6.3. Comparative market share analysis, 2018 & 2026
6.3.7. India
6.3.7.1. Market size and forecast, by cancer form, 2016-2026
6.3.7.2. Market size and forecast, by application, 2016-2026
6.3.7.3. Comparative market share analysis, 2018 & 2026
6.3.8. Australia
6.3.8.1. Market size and forecast, by cancer form, 2016-2026
6.3.8.2. Market size and forecast, by application, 2016-2026
6.3.8.3. Comparative market share analysis, 2018 & 2026
6.3.9. South Korea
6.3.9.1. Market size and forecast, by cancer form, 2016-2026
6.3.9.2. Market size and forecast, by application, 2016-2026
6.3.9.3. Comparative market share analysis, 2018 & 2026
6.3.10. Rest of the Asia Pacific
6.3.10.1. Market size and forecast, by cancer form, 2016-2026
6.3.10.2. Market size and forecast, by application, 2016-2026
6.3.10.3. Comparative market share analysis, 2018 & 2026
6.4. LAMEA
6.4.1. Market size and forecast, by cancer form, 2016-2026
6.4.2. Market size and forecast, by application, 2016-2026
6.4.3. Market size and forecast, by country, 2016-2026
6.4.4. Comparative market share analysis, 2018 & 2026
6.4.5. Brazil
6.4.5.1. Market size and forecast, by cancer form, 2016-2026
6.4.5.2. Market size and forecast, by application, 2016-2026
6.4.5.3. Comparative market share analysis, 2018 & 2026
6.4.6. Saudi Arabia
6.4.6.1. Market size and forecast, by cancer form, 2016-2026
6.4.6.2. Market size and forecast, by application, 2016-2026
6.4.6.3. Comparative market share analysis, 2018 & 2026
6.4.7. South Africa
6.4.7.1. Market size and forecast, by cancer form, 2016-2026
6.4.7.2. Market size and forecast, by application, 2016-2026
6.4.7.3. Comparative market share analysis, 2018 & 2026
6.4.8. Rest of LAMEA
6.4.8.1. Market size and forecast, by cancer form, 2016-2026
6.4.8.2. Market size and forecast, by application, 2016-2026
6.4.8.3. Comparative market share analysis, 2018 & 2026
7. Company Profiles
7.1. AdnaGen GmbH
7.1.1. Business overview
7.1.2. Financial performance
7.1.3. Product portfolio
7.1.4. Recent strategic moves & developments
7.1.5. SWOT analysis
7.2. Advanced Cell Diagnostics, Inc.
7.2.1. Business overview
7.2.2. Financial performance
7.2.3. Product portfolio
7.2.4. Recent strategic moves & developments
7.2.5. SWOT analysis
7.3. AVIVA Biosciences Corporation
7.3.1. Business overview
7.3.2. Financial performance
7.3.3. Product portfolio
7.3.4. Recent strategic moves & developments
7.3.5. SWOT analysis
7.4. Celula, Inc.
7.4.1. Business overview
7.4.2. Financial performance
7.4.3. Product portfolio
7.4.4. Recent strategic moves & developments
7.4.5. SWOT analysis
7.5. Epic Sciences Inc.
7.5.1. Business overview
7.5.2. Financial performance
7.5.3. Product portfolio
7.5.4. Recent strategic moves & developments
7.5.5. SWOT analysis
7.6. Fluxion Biosciences, Inc.
7.6.1. Business overview
7.6.2. Financial performance
7.6.3. Product portfolio
7.6.4. Recent strategic moves & developments
7.6.5. SWOT analysis
7.7. Rarecells USA Inc.
7.7.1. Business overview
7.7.2. Financial performance
7.7.3. Product portfolio
7.7.4. Recent strategic moves & developments
7.7.5. SWOT analysis
7.8. Silicon Biosystems, S.p.A.
7.8.1. Business overview
7.8.2. Financial performance
7.8.3. Product portfolio
7.8.4. Recent strategic moves & developments
7.8.5. SWOT analysis
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
